1. Immunology and Inflammation
  2. Microbiology and Infectious Disease
Download icon

Development of antibody-dependent cell cytotoxicity function in HIV-1 antibodies

  1. Laura E Doepker
  2. Sonja Danon
  3. Elias Harkins
  4. Duncan K Ralph
  5. Zak Yaffe
  6. Meghan E Garrett
  7. Amrit Dhar
  8. Cassia Wagner
  9. Megan M Stumpf
  10. Dana Arenz
  11. James A Williams
  12. Walter Jaoko
  13. Kishor Mandaliya
  14. Kelly K Lee
  15. Frederick A Matsen IV
  16. Julie M Overbaugh  Is a corresponding author
  1. Fred Hutchinson Cancer Research Center, United States
  2. University of Washington, United States
  3. University of Nairobi, Kenya
  4. Coast Provincial General Hospital, Kenya
Research Article
  • Cited 0
  • Views 146
  • Annotations
Cite this article as: eLife 2021;10:e63444 doi: 10.7554/eLife.63444

Abstract

A prerequisite for the design of an HIV vaccine that elicits protective antibodies is understanding the developmental pathways that result in desirable antibody features. The development of antibodies that mediate antibody-dependent cellular cytotoxicity (ADCC) is particularly relevant because such antibodies have been associated with HIV protection in humans. We reconstructed the developmental pathways of six human HIV-specific ADCC antibodies using longitudinal antibody sequencing data. Most of the inferred naïve antibodies did not mediate detectable ADCC. Gain of antigen binding and ADCC function typically required mutations in complementarity determining regions of one or both chains. Enhancement of ADCC potency often required additional mutations in framework regions. Antigen binding affinity and ADCC activity were correlated, but affinity alone was not sufficient to predict ADCC potency. Thus, elicitation of broadly active ADCC antibodies may require mutations that enable high affinity antigen recognition along with mutations that optimize factors contributing to functional ADCC activity.

Article and author information

Author details

  1. Laura E Doepker

    Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4514-5003
  2. Sonja Danon

    Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5399-7081
  3. Elias Harkins

    Computational Biology, Fred Hutchinson Cancer Research Center, Seattle, United States
    Competing interests
    No competing interests declared.
  4. Duncan K Ralph

    Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, United States
    Competing interests
    No competing interests declared.
  5. Zak Yaffe

    Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, United States
    Competing interests
    No competing interests declared.
  6. Meghan E Garrett

    Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, United States
    Competing interests
    No competing interests declared.
  7. Amrit Dhar

    Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, United States
    Competing interests
    No competing interests declared.
  8. Cassia Wagner

    Medical Scientist Training Program, Department of Genome Sciences, University of Washington, Seattle, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9934-7578
  9. Megan M Stumpf

    Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8085-3094
  10. Dana Arenz

    Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, United States
    Competing interests
    No competing interests declared.
  11. James A Williams

    Medicinal Chemistry, University of Washington, Seattle, United States
    Competing interests
    No competing interests declared.
  12. Walter Jaoko

    Medicinal Microbiology, University of Nairobi, Nairobi, Kenya
    Competing interests
    No competing interests declared.
  13. Kishor Mandaliya

    Women's Health Project, Coast Provincial General Hospital, Mombasa, Kenya
    Competing interests
    No competing interests declared.
  14. Kelly K Lee

    Medicinal Chemistry, Microbiology, University of Washington, Seattle, United States
    Competing interests
    No competing interests declared.
  15. Frederick A Matsen IV

    Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0607-6025
  16. Julie M Overbaugh

    Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, United States
    For correspondence
    joverbau@fredhutch.org
    Competing interests
    Julie M Overbaugh, Reviewing editor, eLife.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0239-9444

Funding

National Institutes of Health (R37 AI038518)

  • Julie M Overbaugh

National Institutes of Health (R01 HD103571)

  • Julie M Overbaugh

National Institutes of Health (R01 GM113246)

  • Frederick A Matsen IV

National Institutes of Health (R01 AI146028)

  • Frederick A Matsen IV

National Institutes of Health (T32 AI07140)

  • Laura E Doepker

National Institutes of Health (T32 AI083203)

  • Zak Yaffe

National Institutes of Health (P30 AI027757)

  • Duncan K Ralph

Howard Hughes Medical Institute (Faculty Scholar grant)

  • Frederick A Matsen IV

Simons Foundation (Faculty Scholar grant)

  • Frederick A Matsen IV

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: Approval to conduct this study was provided by the ethical review committees of the University of Nairobi Institutional Review Board, the Fred Hutchinson Cancer Research Center Institutional Review Board (protocol 7776), and the University of Washington Institutional Review Board; Clinical Trial Management System Number RG1000880. Study participants provided written informed consent prior to enrollment.

Reviewing Editor

  1. Satyajit Rath, Indian Institute of Science Education and Research (IISER), India

Publication history

  1. Received: September 25, 2020
  2. Accepted: January 8, 2021
  3. Accepted Manuscript published: January 11, 2021 (version 1)

Copyright

© 2021, Doepker et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 146
    Page views
  • 32
    Downloads
  • 0
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Download citations (links to download the citations from this article in formats compatible with various reference manager tools)

Open citations (links to open the citations from this article in various online reference manager services)

Further reading

    1. Immunology and Inflammation
    2. Medicine
    Danielle Janosevic et al.
    Research Article

    Sepsis is a dynamic state that progresses at variable rates and has life-threatening consequences. Staging patients along the sepsis timeline requires a thorough knowledge of the evolution of cellular and molecular events at the tissue level. Here, we investigated the kidney, an organ central to the pathophysiology of sepsis. Single-cell RNA-sequencing in a murine endotoxemia model revealed the involvement of various cell populations to be temporally organized and highly orchestrated. Endothelial and stromal cells were the first responders. At later time points, epithelial cells upregulated immune-related pathways while concomitantly downregulating physiological functions such as solute homeostasis. Sixteen hours after endotoxin, there was global cell–cell communication failure and organ shutdown. Despite this apparent organ paralysis, upstream regulatory analysis showed significant activity in pathways involved in healing and recovery. This rigorous spatial and temporal definition of murine endotoxemia will uncover precise biomarkers and targets that can help stage and treat human sepsis.

    1. Immunology and Inflammation
    2. Medicine
    Kelsey E Huntington et al.
    Short Report

    Although the range of immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is variable, cytokine storm is observed in a subset of symptomatic individuals. To further understand the disease pathogenesis and, consequently, to develop an additional tool for clinicians to evaluate patients for presumptive intervention we sought to compare plasma cytokine levels between a range of donor and patient samples grouped by a COVID-19 Severity Score (CSS) based on need for hospitalization and oxygen requirement. Here we utilize a mutual information algorithm that classifies the information gain for CSS prediction provided by cytokine expression levels and clinical variables. Using this methodology, we found that a small number of clinical and cytokine expression variables are predictive of presenting COVID-19 disease severity, raising questions about the mechanism by which COVID-19 creates severe illness. The variables that were the most predictive of CSS included clinical variables such as age and abnormal chest x-ray as well as cytokines such as macrophage colony-stimulating factor (M-CSF), interferon-inducible protein 10 (IP-10) and Interleukin-1 Receptor Antagonist (IL-1RA). Our results suggest that SARS-CoV-2 infection causes a plethora of changes in cytokine profiles and that particularly in severely ill patients, these changes are consistent with the presence of Macrophage Activation Syndrome and could furthermore be used as a biomarker to predict disease severity.